ORIC Pharmaceuticals, Inc.

DB:4TZ Stock Report

Market Cap: €1.1b

ORIC Pharmaceuticals Management

Management criteria checks 2/4

ORIC Pharmaceuticals' CEO is Jacob Chacko, appointed in May 2018, has a tenure of 8.17 years. total yearly compensation is $5.57M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth €6.19M. The average tenure of the management team and the board of directors is 7 years and 6.3 years respectively.

Key information

Jacob Chacko

Chief executive officer

US$5.6m

Total compensation

CEO salary percentage11.81%
CEO tenure8.2yrs
CEO ownership0.6%
Management average tenure7yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jacob Chacko's remuneration changed compared to ORIC Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$135m

Dec 31 2025US$6mUS$658k

-US$129m

Sep 30 2025n/an/a

-US$135m

Jun 30 2025n/an/a

-US$137m

Mar 31 2025n/an/a

-US$133m

Dec 31 2024US$5mUS$627k

-US$128m

Sep 30 2024n/an/a

-US$120m

Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$102m

Dec 31 2023US$3mUS$596k

-US$101m

Sep 30 2023n/an/a

-US$93m

Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$4mUS$572k

-US$89m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$7mUS$536k

-US$79m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$81m

Dec 31 2020US$6mUS$489k

-US$74m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$672kUS$456k

-US$27m

Compensation vs Market: Jacob's total compensation ($USD5.57M) is above average for companies of similar size in the German market ($USD1.87M).

Compensation vs Earnings: Jacob's compensation has increased whilst the company is unprofitable.

CEO

Jacob Chacko (47 yo)

8.2yrs
Tenure
US$5,567,164
Compensation

Dr. Jacob M. Chacko, M.D., MBA, is the Chair and Independent Director of Bright Peak Therapeutics AG. Dr. Chacko has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 a...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Heyman
Founder11.3yrsUS$306.02k0.25%
€ 2.7m
Jacob Chacko
President8.2yrsUS$5.57m0.56%
€ 6.2m
Dominic Piscitelli
Chief Financial Officer6.8yrsUS$2.24m0.066%
€ 725.2k
Pratik Multani
Chief Medical Officer7.8yrsUS$2.28m0.066%
€ 725.2k
Charles Sawyers
Founder & Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Founder & Member of Scientific Advisory Boardno datano datano data
Kevin Brodbeck
Chief Technical Officerless than a yearno datano data
Lori Friedman
Chief Scientific Officer7yrsno datano data
Christian Kuhlen
General Counsel6.3yrsno datano data
Daniel Iazzetti
VP & Head of People3.8yrsno datano data
Edna Chow Maneval
Executive Vice President of Clinical Development7.3yrsno datano data
Matthew Panuwat
Chief Business Officer7.7yrsno datano data
7.0yrs
Average Tenure
59yo
Average Age

Experienced Management: 4TZ's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Heyman
Founder11.3yrsUS$306.02k0.25%
€ 2.7m
Jacob Chacko
President8.2yrsUS$5.57m0.56%
€ 6.2m
Charles Sawyers
Founder & Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Founder & Member of Scientific Advisory Boardno datano datano data
Laurence Lasky
Member of Scientific Advisory Boardno datano datano data
Angie You
Independent Director4.7yrsUS$258.52k0.027%
€ 298.0k
Lori Kunkel
Independent Director6.1yrsUS$251.02k0.081%
€ 896.1k
Mardi Dier
Independent Director6.4yrsUS$266.02k0%
€ 0
Steven Hoerter
Independent Director4.9yrsUS$258.52k0%
€ 0
6.3yrs
Average Tenure
64.5yo
Average Age

Experienced Board: 4TZ's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/26 13:51
End of Day Share Price 2026/07/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ORIC Pharmaceuticals, Inc. is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc